Evidence map›Paper›PMID 39805843›Full record

ArticleScientific reports2025

Author Correction: Yindanxinnaotong, a Chinese compound medicine, synergistically attenuates atherosclerosis progress.

Long Cheng, Guo-Feng Pan, Xiao-Dong Zhang, Jian-Lu Wang, Wan-Dan Wang, Jian-Yong Zhang, Hui Wang, Ri-Xin Liang, Xiao-Bo Sun

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Long Cheng *Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100193, P. R. China.
Guo-Feng Pan *Department of Traditional Chinese Medicine, Beijing Shijitan Hospital affiliated With Capital Medical University, Beijing, 100038, P. R. China.
Xiao-Dong Zhang *Center for Drug Evaluation, China Food and Drug Administration, Beijing, 100038, P. R. China.
Jian-Lu WangInstitute of Medicia Materia, China Academy of Chinese Medical Sciences, Beijing, 100700, P. R. China.
Wan-Dan WangInstitute of Medicia Materia, China Academy of Chinese Medical Sciences, Beijing, 100700, P. R. China.
Jian-Yong Zhang *Zunyi Medical University, Zunyi, Guizhou, 563003, P. R. China.
Hui WangGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, P. R. China.
Ri-Xin LiangInstitute of Medicia Materia, China Academy of Chinese Medical Sciences, Beijing, 100700, P. R. China. liangrixin2009@sina.com.
Xiao-Bo SunKey Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100193, P. R. China. sun-xiaobo@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39805843
PMCPMC11729886

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.